Florent Suau

Florent Suau

Auto-generated profile, based on publicly available information

Florent Suau

Department of Microbiology, Faculty of Pharmacy, Dicle University, Diyarbakir 21280, Turkey

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2017 in Science Signaling
Verified
Journal Article
Closed access
PDF file
WCWei-Yu Chen
Wei-Yu Chen
YTYuan-Chin Tsai
Yuan-Chin Tsai
HYHsiu-Lien Yeh
Hsiu-Lien Yeh
FSFlorent Suau
Florent Suau
KJKuo-Ching Jiang
Kuo-Ching Jiang
YLYen-Nien Liu
Yen-Nien Liu
Androgen deprivation therapy (ADT) targeting the androgen receptor (AR) is a standard therapeutic regimen for treating prostate cancer. However, most tumors progress to metastatic castration-resistant prostate cancer after ADT. We identified the type 1, 2, and 4 collagen–binding protein transforming growth factor–β (TGFβ)–induced protein (TGFBI) as an important factor in the epithelial-to-mesenchymal transition (EMT) and malignant progression of prostate cancer. In prostate cancer cell lines, AR signaling stimulated the activity of the transcription factor SPDEF, which repressed the expression of TGFBI. ADT, AR antagonism, or overexpression of TGFBI inhibited the activity of SPDEF and enhanced the proliferation rates of prostate cancer cells. Knockdown of TGFBI suppressed migration and proliferation in cultured cells and reduced prostate tumor growth and brain and bone metastasis in xenograft models, extending the survival of tumor-bearing mice. Analysis of prostate tissue samples collected before and after ADT from the same patients showed that ADT reduced the nuclear abundance of SPDEF and increased the production of TGFBI. Our findings suggest that induction of TGFBI promotes prostate cancer growth and metastasis and can be caused by dysregulation or therapeutic inhibition of AR signaling.